MOTNF yields 20000000.00% · JNJ yields 2.13%● Live data
📍 MOTNF pulled ahead of the other in Year 1
Combined, MOTNF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MOTNF + JNJ for your $10,000?
Powertap Hydrogen Capital Corp. is a venture capital firm specializing in investments in early stage, buyouts. It prefers to invest in equity, bridge loans, secured loans, unsecured loans, convertible debentures, warrants and options, joint ventures, partnerships, royalties, streaming investments, net profit interests and other hybrid instruments. It focuses its investments in energy sector, oil and gas equipment and commercial aircraft sector. The firm prefers to invest in securities of private and publicly listed entities that are involved in a variety of industries including renewable energy includes hydrogen & fuel cell technologies, wind power, solar power and geothermal power. The firm invests bio-medical, pharmaceutical, and naturopathic sectors, which may include medical or recreational cannabis. The firm prefers to focus on investing in cannabis enterprises. The firm considers investments in North America. The firm does not invest in Canada and United States. The firm takes control position and majority stake in the companies. The company was formerly known as Clean Power Capital Corp. and changed its name to Powertap Hydrogen Capital Corp. in June 2021. Powertap Hydrogen Capital Corp. was founded in 1980 and is headquartered in Vancouver, Canada with additional offices in Hamilton, Bermuda and London, United Kingdom.
Full MOTNF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.